dioxadet has been researched along with Peritoneal Carcinomatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA | 1 |
| Alexeev, VV; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Gafton, GI; Guseinov, KD; Kireeva, GS; Senchik, KY; Soloviev, LA; Stukov, AN; Vasilchenko, MV | 1 |
2 other study(ies) available for dioxadet and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines | 2015 |
[Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Female; Hyperthermia, Induced; Intraoperative Period; Ovarian Neoplasms; Peritoneal Cavity; Peritoneal Neoplasms; Rats; Rats, Wistar; Survival Analysis; Triazines | 2015 |